HELIO, a leading boutique compliance consulting and SaaS technology firm for the life sciences industry, announces the appointment of Chris Cobourn and Joe Skupen, effective April 1st. Both executives will oversee the emerging government pricing (GP) practice within HELIO.

HELIO, a tech-enabled professional services organization is proud to announce the expansion of its communications monitoring capabilities to support over 100 languages. This marks another milestone in HELIO AI’s Compliance Solutions for the Life Sciences industry and beyond.

HELIO, a tech-enabled professional services organization, has successfully launched HelioChat (their ChatGPT-like solution) to a Top 20 Pharmaceutical company through its newly formed HELIO AI suite of solutions. This marks another milestone in HELIO AI’s product set designed for the Life Sciences industry.

Patient-support services programs have become common in the pharmaceutical industry and are now considered table stakes for certain disease states. Yet recent government scrutiny has left some pharma companies wondering what to do with these programs in the future.

In line with a general call for more “patient centricity,” pharma companies have been stepping up their patient support services, often managed through outsourced hub providers. This is generally a good thing, both for patients and for brand owners themselves; but …

Fourteen-year-old Carson Domey recently injected himself with his Crohn’s disease medication for the first time. But he didn’t quite position the injector properly, so some of the clear liquid accidentally leaked down his leg.

United Therapeutics (UTHR) agreed to pay $210 million to resolve charges of paying kickbacks to Medicare patients through an ostensibly independent charity, one of the first settlements to emerge from an investigation into drug makers that deal with charities to provide financial assistance to patients.

For the past four years, the federal government has required drug makers to report any meals they buy for doctors, as well as any payments for speaking, consulting, and running clinical trials.

Pharma needs better internal policies to manage its increasing patient interaction. It’s axiomatic that the trend toward specialty pharmaceuticals is expanding the range of patient-oriented services that the pharma industry is involved in: the very definition of a specialty pharmaceutical includes ones that require patient support.